Employees of the American pharmaceutical company Aprecia Pharmaceuticals have received permission from the FDA (Food and Drug Administration - the Food and Drug Administration) to use 3D printing technology to create drugs. Spritam (Levetiracetam) was the first drug that was created using a 3D printer.
The medication is used by adults and children to prevent the development of epileptic seizures. In Russia, Levetiracetam is on the list of vital and essential medicines approved by the Government of the Russian Federation.
The new technology for creating Sprite, called ZipDose, was developed by specialists from the Massachusetts Institute of Technology (Massachusetts Institute of Technology). Using it, tablets do not consist of “compressed” drug layers, but have a porous structure. This type of production allows for faster dissolution and better absorption of the drug. Also, as noted by pharmaceutical company employees, this technique simplifies medication for patients who have difficulty swallowing tablets.
Don Wetherhold, CEO of Aprecia Pharmaceuticals, said the technology could be used to create drugs for patients suffering from diseases such as schizophrenia, Parkinson's disease, or other disorders.
“Sprite is a drug that has changed our understanding of antiepileptic drugs; in our product line, he is the first to offer doctors and their patients additional treatment options. ”
In January 2016, Aprecia Pharmaceuticals received a $ 35 million investment from the Deerfield Management Fund. Currently, the company has an exclusive international license for the pharmaceutical use of 3D printing technology.
The article is based on materials .
Comments
Post a Comment